Animal experiment:

Male mice (26-30 g) are anesthetized, artificially ventilated, and placed on a heated jacket to control body temperature. A femoral vein is cannulated for i.v. injections. In thrombosis experiments, drugs including SR121566A are administered in 0.9% saline for intravenous studies (0.1 mL/30 g, 5 min before stimulation) and in water for oral studies (0.1 mL/30 g, 120 min before stimulation)[2].

SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of 46±7.5, 56±6 and 42±3 nM, respectively.

SR121566A leads to dose-dependent increases in TTO, a statistically significant increase being observed at the doses of 0.3 mg/kg (473%) and 30 mg/kg (771%), respectively[2].

[1]. Herault JP，et al. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost. 1998 Feb;79(2):383-8. [2]. Lorrain J, et al. Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel. J Pharmacol Exp Ther. 2004 Apr;309(1):235-40.